Company: SINT
Filing Date: 2025-11-12
Form Type: 10-Q
Source: 0001493152-25-021930
Chunk: 28

Company: Sintx Technologies, Inc.
Filing Date: 2025-11-12
Form: 10-Q
Item: Item 8
Chunk 28
---
 89%, compared to the same period in
2024, primarily due to the decrease in grant and contract revenue associated with the sale of the TA&T subsidiary.

Other
income, net

For
the three months ended September 30, 2025, other income decreased $0.4 million, or 209%, compared to the same period in 2024, primarily
due to a $0.4 million decrease in the change in value of derivative liabilities.

For
the nine months ended September 30, 2025, other income decreased $2.7 million, or 91%, compared to the same period in 2024, primarily
due to a $3.1 million decrease in the change in value of derivative liabilities, partially offset by a $0.3 million gain on disposal
of property and equipment associated with SINTX Armor, and a $0.1 million increase in interest income.

Liquidity
and capital resources 

The
condensed consolidated financial statements have been prepared assuming we will continue to operate as a going concern, which
contemplates the realization of assets and settlement of liabilities in the normal course of business, and does not include any adjustments
to reflect the possible future effects on the recoverability and classification of assets or the amounts and classifications of liabilities
that may result from uncertainty related to our ability to continue as a going concern within one year from the date of issuance of these
condensed consolidated financial statements.

For
the nine months ended September 30, 2025, and 2024, we incurred a net loss of $8.1 million and $9.3 million, respectively, and
used cash in operating activities of $6.2 million and $7.5 million, respectively. We had an accumulated deficit of $290 million
and $282 million as of September 30, 2025, and December 31, 2024, respectively. We will require substantial future capital in order to
continue operating our business, conduct research and development and regulatory clearance and approval activities necessary to bring
our products to market, and to establish effective marketing and sales capabilities. Our existing capital resources may not be sufficient
to enable us to fund the completion of the development and commercialization of all our product candidates.

To
date, our operations have been principally financed from proceeds from the issuance of preferred and common stock and,
to a lesser extent, cash generated from product sales. We expect that we will continue to generate operating losses
and use cash